Windlas Biotech Q1FY27 Revenue up 18% to ₹248 Crore; PAT at ₹25 Crore
Windlas Biotech reported Q1FY27 revenue of ₹248 crore, an 18% YoY increase, marking its 14th consecutive quarter of record revenue. Adjusted PAT grew 37% YoY to ₹25 crore. The company completed a ₹47 crore buyback and declared a ₹13 crore dividend for FY26. Generic Formulations CDMO revenue rose 29% YoY.
The announcement details robust financial performance with significant year-on-year growth in revenue and profits, alongside strategic corporate actions like a buyback and dividend. These factors are material and likely to influence investor perception and stock performance.
The company reported strong revenue growth, significant increases in EBITDA and PAT, and improved EPS, indicating a positive financial performance. The completion of a buyback and dividend payout further support a positive sentiment.
Windlas Biotech Limited has reported its financial results for the first quarter of FY27 (Q1FY27), showcasing a robust performance with an 18% year-on-year (YoY) growth in revenue, reaching ₹248 crore. This marks the 14th consecutive quarter of record revenue for the company.
The company highlighted strong operational leverage improvements. Excluding non-cash ESOP expenses of ₹7.2 crore, EBITDA grew by 26% YoY to ₹34 crore, while Profit Before Tax (PBT) and Profit After Tax (PAT) increased by 27% and 37% YoY to ₹30 crore and ₹25 crore, respectively. Including ESOP expenses, reported EBITDA was ₹27 crore, PBT ₹23 crore, and PAT ₹18 crore. The Earnings Per Share (EPS) for Q1FY27 improved to ₹8.46.
In terms of business verticals, the Generic Formulations CDMO segment recorded a 29% YoY revenue growth to ₹207 crore, driven by customer expansion, deeper engagement, and new product launches. The Trade Generics & Institutional segment reported ₹30 crore in revenue, impacted by the discontinuation of certain codeine-based products, with expectations to bridge the gap through new launches. The Exports vertical saw a significant 79% YoY growth to ₹11 crore.
The company also completed a share buyback of ₹47 crore in Q1FY27, in which promoters did not participate. Additionally, a dividend of ₹13 crore (₹6.30 per equity share) for FY26 was declared.
Looking ahead, Windlas Biotech remains focused on strengthening strategic partnerships, expanding its offerings, achieving operational excellence, accelerating portfolio development, and disciplined execution. The commercialization of Plant-6 is on track for H1 FY27, which is expected to further bolster manufacturing capacity. The company continues to prioritize long-term value creation through its diversified business model and strategic investments.
What to do with a filing like this
Windlas Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Windlas Biotech Limited. Read the original for the full detail.